The results not only suggested that FDX1 might be a potent prognostic biomarker, which was closely associated with cancer immunomodulatory mechanisms and resistance to antitumor drugs, but also revealed its as a potential predictor of pan-cancer immunotherapy. Here, FDX1 is linked to cancer.